Veracyte (VCYT) Receivables (2012 - 2026)

Veracyte has disclosed Receivables across 15 years of filings, most recently posting $50.1 million for Q1 2026.

• Receivables for Q1 2026 came in at $50.1 million, down 6.82% year-over-year; the trailing twelve-month figure through Mar 2026 was $50.1 million (down 6.82% YoY), and the FY2025 annual result was $44.7 million, down 4.01% from the prior year.
• Receivables came in at $50.1 million for Q1 2026 at Veracyte, up from $44.7 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $53.8 million in Q1 2025 to a low of $39.3 million in Q3 2023.
• The 5-year median for Receivables is $45.5 million (2023), against an average of $45.5 million.
• Across the five-year window, Receivables jumped 52.39% in 2022 and dropped 8.28% in 2023, its largest moves.
• Veracyte's Receivables stood at $44.0 million in 2022, then dropped by 8.28% to $40.4 million in 2023, then rose by 15.22% to $46.5 million in 2024, then fell by 4.01% to $44.7 million in 2025, then increased by 12.21% to $50.1 million in 2026.
• The last three Receivables figures came in at $50.1 million (Q1 2026), $44.7 million (Q4 2025), and $47.8 million (Q3 2025), per Business Quant data.